News & Events
In the news
Our January webinar is now available for replay!
« Solutions for gene therapy products GMP biosafety testing – Focus on lentiviral vectors ».
You will find below the youtube link to our latest webinar "Solutions for gene therapy products GMP biosafety testing – Focus on lentiviral vectors" co-hosted by Xavier LECLERC and Aymeric HUGUENOT. An opportunity to watch and share the online event from 14 January!
Save the date ! New webinaire on January 14, 2021
Solutions for gene therapy products GMP biosafety testing – Focus on lentiviral vectors
Our newest addition to our webinar series will address the matter of GMP biosafety testing of gene therapy products. Join Dr Xavier Leclerc on 14 JAN 2020 to discover how Clean Cells provides solutions for gene therapies in a talk focusing on the detection of replicative lentiviral particles.
Our very first webinar is now streaming!
"Cytotoxicity testing solutions for ADCC, CDC and apoptosis"
You missed the webinar and would like to catch up or you’re looking like to watch the session again? The talk is now streaming on this page.
Webinar – 1st october 2020
"Cytotoxicity testing solutions for ADCC, CDC and apoptosis"
Come to discover our solutions to characterize your mAb products through a presentation of our Cytotoxicity assay (ADCC, CDC, apoptosis) during a webinar presented by Alexis Rossignol, PhD project manager and Bio assay specialist at Clean Cells.
Covid-19 information
Let us know if we can support you
Clean Cells, specialized in the detection of biological contaminant is always committed to contribute to the development of innovative drugs.
Covid-19 information
Clean Cells maintains its usual level of activity
In the context of the coronavirus (CoviD-19) epidemic, Clean Cells' teams are closely monitoring the evolution of the situation in order to guarantee business continuity but also to protect the safety and health of our employees.
BE Vaccines is now NAOBIOS
After joining Clean Cells on March 1st, 2019, BE Vaccines has been renamed NAOBIOS.
Created originally by the Valneva Group (ex-Vivalis) in 2005, then taken over by the Indian company Biological E in 2013 with the aim of stepping up the technical development of viral vaccines, BE VACCINES joined CLEAN CELLS on March 1st, 2019.
Press Release
CLEAN CELLS acquires BE VACCINES and demonstrates its development ambitions
On March 1st, 2019, Clean Cells acquired BE Vaccines, a French subsidiary of the Indian Pharmaceutical Company Biological E. Limited (BE).